HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MI 319

has antineoplastic activity; structure in first source

Also Known As:

MI-319; MI319 cpd

Networked: 5 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - MI 319: 5
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Spiro Compounds: 2
      - MI 319: 5
Polycyclic Compounds: 6
- Spiro Compounds: 2
  - MI 319: 5

Experts

1.	Mohammad, Ramzi M: 4 articles (09/2012 - 12/2009)
2.	Azmi, Asfar S: 3 articles (05/2010 - 12/2009)
3.	Yang, Dajun: 3 articles (05/2010 - 12/2009)
4.	Al-Katib, Ayad M: 2 articles (09/2012 - 12/2009)
5.	Banerjee, Sanjeev: 2 articles (05/2010 - 04/2010)
6.	Philip, Philip A: 2 articles (05/2010 - 04/2010)
7.	Sarkar, Fazlul H: 2 articles (05/2010 - 04/2010)
8.	Wang, Zhiwei: 2 articles (05/2010 - 04/2010)
9.	Aboukameel, Amro: 2 articles (04/2010 - 12/2009)
10.	Wang, Shaomeng: 2 articles (04/2010 - 12/2009)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 05/01/2010 - "The present study is the first to show in pancreatic cancer (PC) the growth inhibition and apoptosis by novel MDM2 inhibitors (MI-319 & 219) through reactivation of p53 pathway. " 04/01/2010 - "MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function." 04/01/2010 - "In this study we are reporting, for the first time, that MI-319 in combination with cisplatin induced cell growth inhibition and apoptosis in pancreatic cancer (PC) cells irrespective of their p53 mutational status. "
2.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/03/2009 - "The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. " 09/18/2012 - "Previously, we examined the anti-lymphoma activity of MI-319, the laboratory grade of a new class of HDM2 SMI, the spiro-oxindole, in follicular lymphoma. "
3.	Lymphoma (Lymphomas) 12/03/2009 - "In our systemic mouse model for FSCCL, MI-319 was tolerated well by the animals, displayed effectiveness against FSCCL-lymphoma cells in blood, brain and bone marrow, and achieved significant therapeutic impact (p < 0.0001) by conferring the treatment group a > 28% (%ILS, 14.4 days) increase in median survival days. " 12/03/2009 - "The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. " 09/18/2012 - "Previously, we examined the anti-lymphoma activity of MI-319, the laboratory grade of a new class of HDM2 SMI, the spiro-oxindole, in follicular lymphoma. " 12/03/2009 - "Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and Nutlin-3. "
4.	Neoplasms (Cancer) 05/01/2010 - "Further, using wt-p53 xenograft of Capan-2, we found that oral administration of MI-319 at 300 mg/kg for 14 days resulted in significant tumor growth inhibition without any observed toxicity to the animals. " 09/19/2011 - "In A375 xenografts, the antitumor effects of sorafenib and MI-319 were additive and associated with the down modulation of Bcl-2 and Bcl-xL, the nuclear translocation of AIF, and increased suppression of tumor angiogenesis. "
5.	Melanoma (Melanoma, Malignant) 09/19/2011 - "MI-319 alone increased p53 levels and p53-dependent gene expression in melanoma cells but did not induce programmed cell death. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Sorafenib (BAY 43-9006)
3.	MI-219
4.	nutlin 3
5.	2-oxindole (oxindole)

Related Therapies and Procedures

1.	Oral Administration